Risk factor
Very poor trading liquidity
Profitability factor
Favourable analyst view
About
Scope Fluidics S.A. is a biotechnology firm dedicated to conceiving and advancing initiatives that harness microfluidic technologies within medical diagnostics and the broader healthcare landscape. Among its key offerings is BacterOMIC, a specialized system for conducting antibiotic susceptibility testing. This enterprise, established in 2010, conducts its operations from Warsaw, Poland.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is underpriced on P/E, 'expensive' on
Target Price
The average target price of SCP.WA is 198 and suggests 67.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc